The U.S. Food and Drug Administration approved oveporexton, marketed as Orzeyful, on August 5, 2026. It is the first orexin receptor agonist cleared to treat narcolepsy type 1 in adults, and it is taken as a twice-daily oral tablet.
Existing narcolepsy therapies, mostly stimulants and sodium oxybates, work on downstream symptoms like daytime drowsiness. Orzeyful, from Takeda, targets the biological gap that causes the disease itself.
People with narcolepsy type 1 lose the brain cells that make orexin, a brain chemical the NIH describes as central to keeping us awake and regulating REM sleep. Without it, patients slip into sudden sleep and experience cataplexy, brief episodes of muscle weakness often triggered by emotion.
How it worked in trials
Approval was based on two 12-week Phase 3 studies called FirstLight and RadiantLight. FirstLight enrolled 168 adults and RadiantLight enrolled 105, with patients randomized to oveporexton or placebo.
Also read: New hope for Céline Dion as researchers test promising treatment
Both studies met their primary endpoint, an improvement on the Maintenance of Wakefulness Test. They also met key secondary endpoints, including Epworth Sleepiness Scale scores and weekly cataplexy rate.
Around 85 percent of participants on the 2 mg dose reached an Epworth score of 10 or below, in line with people who do not have a sleep disorder. Median weekly cataplexy attacks dropped by more than 80 percent from baseline.
"The FDA approval of ORZEYFUL marks a new chapter for the narcolepsy type 1 community, as we introduce an entirely new class of medicine that will potentially redefine how this disease is managed and how people feel on treatment," Julie Kim, president and CEO of Takeda, said in the company's announcement.
What patients need to know
The drug is not without side effects. In the trials the most common reactions on the 2 mg dose were insomnia, reported by 60 percent of participants versus 1 percent on placebo, and urinary frequency, reported by 58 percent versus 5 percent.
Also read: Moderna's mRNA flu shot cleared for older adults ahead of the 2026-27 flu season
Asymptomatic elevations in creatine phosphokinase, a muscle enzyme, above five times the upper limit of normal were seen in 11 percent of participants, compared with 5 percent on placebo. Orzeyful is contraindicated for patients taking strong CYP3A inhibitors, a class of medicines that block a key liver enzyme.
Availability will not be immediate. The Drug Enforcement Administration has to finish a controlled-substance scheduling review, expected within 90 days, before the drug can be dispensed through specialty pharmacies.
A wider question about diagnosis
Takeda estimates that about 120,000 Americans have narcolepsy type 1, but the disease is widely missed. A recent U.S. patient survey published in the NIH-hosted PubMed Central found that nearly a third of respondents received a definitive diagnosis 10 or more years after first raising the issue with a clinician, and most had been diagnosed with depression along the way.
Dr. Emmanuel Mignot, principal U.S. investigator in the Orzeyful Phase 3 program, framed the approval as a shift in what a doctor can offer. "Until now, people have managed narcolepsy type 1 with treatments that target symptom relief. As the first and only approved orexin therapy to treat the broad spectrum of the disease, ORZEYFUL can enable a different kind of conversation in the doctor's office about treatment options," he said in Takeda's release.
Also read: 8 foods that may improve sleep quality, according to a 2026 review of melatonin-rich diets
Patient advocates called the moment overdue. "For those of us living with narcolepsy type 1, symptoms reshape everyday life and extend far beyond what most people understand about the condition. ORZEYFUL's approval is a historic moment that expands our treatment choices," said Julie Flygare, president and CEO of the nonprofit Project Sleep and a person with narcolepsy type 1.
Anyone who suspects they may be sleeping through their days, or losing muscle tone when they laugh or feel strong emotion, should raise it with a doctor rather than self-diagnose.
Also read: One open window could fix the bedroom air that is quietly dragging down your sleep